A consideration of convalescent plasma and plasma derivatives in the care of Severely-ill patients with COVID-19.
Transfus Apher Sci
; 59(5): 102936, 2020 Oct.
Article
in English
| MEDLINE | ID: covidwho-748038
ABSTRACT
The pathogenesis and immunopathological damage of severe forms of COVID-19 resemble acute autoimmune disease sparked by SARS-CoV-2, including an early systemic overproduction of proinflammatory cytokines. Such immunopathological features provide a rationale for the use of passive immunotherapy with convalescent plasma as a source of neutralizing anti-viral antibodies and of anti-inflammatory plasma components. While convalescent plasma therapy is now being evaluated in prospective clinical trials, we further consider the therapeutic potential of human hyper immune globulins, and of heterologous, engineered and monoclonal neutralizing antibodies as anti-viral agents to treat COVID-19. Good medical practice procedures are still needed and is why we also discuss the potential use of polyclonal polyspecific immunoglobulins (IVIG), a therapeutic plasma derivative, with potent anti-inflammatory activity, in severe forms of Covid-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Plasma
/
Severity of Illness Index
/
COVID-19
Type of study:
Diagnostic study
/
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Transfus Apher Sci
Journal subject:
Hematology
Year:
2020
Document Type:
Article
Affiliation country:
J.transci.2020.102936
Similar
MEDLINE
...
LILACS
LIS